Fore Biotherapeutics is a precision oncology company specializing in cancer therapies guided by functional genomics.
Fore Biotherapeutics has raised $67.4M in total funding. The most recent round was Series D. The last funding was announced in July 2026.
Fore Biotherapeutics's investors include Wellington Management, Cormorant Asset Management, OrbiMed, SR One, Medicxi.
Fore Biotherapeutics is headquartered in Philadelphia, United States.
Fore Biotherapeutics is a precision oncology company specializing in cancer therapies guided by functional genomics.
Fore Biotherapeutics is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Fore Biotherapeutics — Funding & Investors." VCBacked, July 7, 2026, https://www.vcbacked.co/company/fore-biotherapeutics. Accessed September 2, 2026.
VCBacked. (2026). Fore Biotherapeutics — Funding & Investors. Retrieved September 2, 2026, from https://www.vcbacked.co/company/fore-biotherapeutics
{{cite web |title=Fore Biotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/fore-biotherapeutics |website=VCBacked |access-date=September 2, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated